{"id":"NCT00433160","sponsor":"Eli Lilly and Company","briefTitle":"Phase 3 Clinical Trial of Teriparatide in Japan","officialTitle":"Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2008-09","completion":"2009-09","firstPosted":"2007-02-09","resultsPosted":"2009-09-30","lastUpdate":"2010-09-21"},"enrollment":207,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"Teriparatide","otherNames":["LY333334","Forteo","Forsteo"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Teriparatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy of teriparatide based on measurements of bone mineral density at lumbar spine","primaryOutcome":{"measure":"Percent Change in Bone Mineral Density at Lumbar Spine (L2-L4)","timeFrame":"Baseline to 52 weeks","effectByArm":[{"arm":"Teriparatide","deltaMin":9.82,"sd":5.36},{"arm":"Placebo","deltaMin":0.04,"sd":4.34}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":["20580870","26185429"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":136},"commonTop":["Nasopharyngitis","Back pain","Fall","Contusion","Osteoarthritis"]}}